德国、日本和我国台湾地区药品价格规制经验及启示

发布时间：2018-03-27 10:43

  本文选题：药品价格　切入点：德国　出处：《中国药房》2017年25期

【摘要】：目的:为完善我国药品价格规制政策提供参考。方法:运用文献研究、制度比较等方法,归纳总结德国、日本和我国台湾地区药品价格规制政策的共性和特色,借鉴其成功经验。结果与结论:德国、日本和我国台湾地区药品价格管理各有特色。德国实行参考价格制度和新药定价机制,是最早实行参考价格制度的国家;日本采用新药创新性加价、仿制药递减定价和药品价格再调整体制;我国台湾地区实行分类分组差别定价、鼓励竞争议价并定期对药价调查与调价。德国、日本和我国台湾地区均将医保支付价作为药价管理的核心,采取综合手段规制药品价格,同时也都注重对市场价格的监测和定期调整,价格谈判和药物经济学等多种定价方法被广泛应用。以价值为基础的定价是目前药品价格政策改革的趋势,我国在完善药品价格管理制度时可有所借鉴。
[Abstract]:Objective: to provide a reference for perfecting the policy of drug price regulation in China. Methods: by means of literature research and institutional comparison, the common features and characteristics of drug price regulation policies in Germany, Japan and Taiwan were summarized. Results and conclusions: drug price management in Germany, Japan and Taiwan has its own characteristics. Germany implements reference price system and new drug pricing mechanism, which is the first country to implement reference price system. Japan uses innovative new drug price increase, generic drug decline pricing and drug price readjustment system; Taiwan region of China implements classified grouping and differential pricing, encourages competition and bargaining, and regularly investigates and adjusts drug prices. Both Japan and Taiwan take the medical insurance payment price as the core of drug price management and adopt comprehensive measures to regulate drug prices. At the same time, they also attach importance to the monitoring and regular adjustment of market prices. Many pricing methods, such as price negotiation and pharmacoeconomics, are widely used. Value-based pricing is the trend of drug price policy reform at present, which can be used for reference in perfecting the drug price management system in China.
【作者单位】： 北京大学药学院药事管理与临床药学系;北京大学医药管理国际研究中心;
【基金】：国家自然科学基金青年项目(No.71503017)
【分类号】：R95
，

本文编号：1671175